Answers are grounded in this paper and cite their sources.
Background: One effective second-generation triptan for migraine attacks is sumatriptan. Following oral use, it has a 40% restricted bioavailability because of the first-pass metabolism. Aim: To develop the best intranasal Solusomes formula as a substitute that delivers into the brain directly, improving its bioavailability, and removing the first-pass outcome was the aim of this effort. Methodology: We developed solute formulations based on the Box-Behnken design and subsequently produced them via thin-film hydration. The quality by design technique was used to establish a correlation between the formulation parameters (Soluplus® and phosphatidylcholine (PC) concentrations) and signif¬icant quality powers (entrapment efficiency (EE%), vesicle size (VS), and polydispersity index (PDI)). Fourier trans¬form infrared spectroscopy (FTIR), optical microscopy, and an in vitro diffusion study were performed on the revised formula. Results: The enhanced formulation exhibited a VS of 93.76 nm, an EE% of 83.65%, and PDI 0.3362 with the least amount of error between the projected and observed values. Conclusion: This study offered a feasible and efficient intranasal formulation appropriate for further brain delivery research.
No takes yet. Share an insight, caveat, or question.
Salman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: